Nature of the Disclosure

This is a regulatory filing submitted to the BSE Limited and the National Stock Exchange of India Limited. It is a revised investor presentation for the quarter ended June 30, 2026 (Q1 FY27), filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The revision supersedes a previous presentation filed on August 13, 2026.

Key Revisions and Corrections

The filing specifically corrects and adds disclosures to two slides in the investor presentation:

  • Slide 25 (Standalone Financials): An additional disclosure states: "Major Expense being one time marketing cost of Rs. 253.24 lakhs of SID and ERICA." The Adjusted EBITDA disclosure was corrected to read: "Adjusted EBITDA is Rs. 507.75 lakhs being 37.12% EBITDA margin."
  • Slide 26 (Consolidated Financials): An additional disclosure states: "Major Expense being one time marketing cost of Rs. 253.24 lakhs of SID and ERICA." The Adjusted EBITDA disclosure was corrected to read: "Adjusted EBITDA is Rs. 532.75 lakhs being 27.49% EBITDA margin."

Business and Operational Highlights from the Presentation

The enclosed investor presentation provides a comprehensive business overview:

  • Company Foundation: Founded in March 2015 by Dr. Manika Khanna and Dr. Peeyush Khanna.
  • Network: Operates a hub-and-spoke model with 8 hubs and 28 spokes across 9 states in India.
  • AI Initiatives: Highlights the deployment of AI tools SID and ERICA, stating it is the first in India and second outside the US to introduce them. Early results indicate an 8-9% increase in success rates.
  • Clinical Metrics: Reports a success rate of 62% on the first attempt and 85% for multiple attempts. The number of Oocyte Pick-Ups (OPU) was 367, and the Average Revenue Per Patient is ₹3.5 lakhs.
  • Growth Strategy: Plans a rapid expansion with 8 new centers planned for FY27 and 1 new center for FY28.
  • Market Data: As of June 30, 2026, the share price was ₹112.95, with 7,27,86,884 shares outstanding, resulting in a market capitalization of ₹822.13 crore. The company is classified as a Healthcare Service Provider.

Financial Impact

The one-time marketing expense of ₹253.24 lakhs for SID and ERICA is explicitly quantified and identified as a major factor affecting the quarter's expenses and EBITDA margins. The financial impact of the expansion-related costs (new hub setups, clinical hiring) is described as a conscious front-loading of investments made ahead of associated revenue.